Free Trial

Emerald Mutual Fund Advisers Trust Lowers Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BridgeBio Pharma logo with Medical background

Emerald Mutual Fund Advisers Trust decreased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 724,872 shares of the company's stock after selling 26,483 shares during the quarter. BridgeBio Pharma makes up 1.2% of Emerald Mutual Fund Advisers Trust's holdings, making the stock its 27th biggest position. Emerald Mutual Fund Advisers Trust owned about 0.38% of BridgeBio Pharma worth $19,890,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Northern Trust Corp boosted its holdings in BridgeBio Pharma by 3.4% in the 4th quarter. Northern Trust Corp now owns 1,323,258 shares of the company's stock worth $36,310,000 after buying an additional 43,955 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of BridgeBio Pharma by 23.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 1,885,794 shares of the company's stock worth $51,746,000 after acquiring an additional 353,570 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of BridgeBio Pharma during the fourth quarter worth approximately $6,531,000. Virtus ETF Advisers LLC raised its stake in BridgeBio Pharma by 11.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 12,637 shares of the company's stock valued at $347,000 after purchasing an additional 1,280 shares during the last quarter. Finally, Nebula Research & Development LLC lifted its holdings in BridgeBio Pharma by 92.4% in the 4th quarter. Nebula Research & Development LLC now owns 36,239 shares of the company's stock valued at $994,000 after purchasing an additional 17,400 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on BBIO. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $95.00 price objective on shares of BridgeBio Pharma in a research note on Friday, February 21st. UBS Group increased their price target on BridgeBio Pharma from $65.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday. JPMorgan Chase & Co. boosted their price objective on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a research note on Monday, March 24th. Redburn Atlantic began coverage on BridgeBio Pharma in a research note on Monday, March 31st. They issued a "buy" rating and a $50.00 target price for the company. Finally, HC Wainwright boosted their price target on shares of BridgeBio Pharma from $49.00 to $53.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, BridgeBio Pharma currently has an average rating of "Moderate Buy" and an average price target of $57.09.

Get Our Latest Analysis on BridgeBio Pharma

Insider Transactions at BridgeBio Pharma

In related news, CEO Neil Kumar sold 75,000 shares of the stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $34.11, for a total transaction of $2,558,250.00. Following the transaction, the chief executive officer now owns 4,873,447 shares of the company's stock, valued at approximately $166,233,277.17. This represents a 1.52 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brian C. Stephenson sold 4,148 shares of the firm's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $36.16, for a total value of $149,991.68. Following the transaction, the chief financial officer now owns 102,464 shares of the company's stock, valued at $3,705,098.24. This trade represents a 3.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,309,191 shares of company stock worth $208,544,821 over the last ninety days. Company insiders own 24.66% of the company's stock.

BridgeBio Pharma Trading Up 0.4 %

NASDAQ BBIO traded up $0.17 during trading hours on Friday, reaching $38.57. The company had a trading volume of 3,168,027 shares, compared to its average volume of 2,352,389. The stock has a market capitalization of $7.32 billion, a P/E ratio of -13.53 and a beta of 1.15. The stock has a 50-day moving average of $34.06 and a 200 day moving average of $30.91. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $39.54.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, topping analysts' consensus estimates of ($1.00) by $0.12. The company had revenue of $36.74 million for the quarter, compared to analysts' expectations of $57.14 million. During the same period in the previous year, the business posted ($0.20) EPS. The business's revenue for the quarter was down 44.8% on a year-over-year basis. As a group, sell-side analysts predict that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

BridgeBio Pharma Company Profile

(Free Report)

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

Further Reading

Institutional Ownership by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

Should You Invest $1,000 in BridgeBio Pharma Right Now?

Before you consider BridgeBio Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.

While BridgeBio Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines